Global Cox-2 Inhibitors Market Growth (Status and Outlook) 2023-2029

Global Cox-2 Inhibitors Market Growth (Status and Outlook) 2023-2029

Cox-2 Inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, Cox-2, an enzyme responsible for inflammation and pain. These drugs are responsible for decreasing the production of prostaglandins.

LPI (LP Information)' newest research report, the “Cox-2 Inhibitors Industry Forecast” looks at past sales and reviews total world Cox-2 Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Cox-2 Inhibitors sales for 2023 through 2029. With Cox-2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cox-2 Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Cox-2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cox-2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cox-2 Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cox-2 Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cox-2 Inhibitors.

The global Cox-2 Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cox-2 Inhibitors players cover Bayer, Novartis, Pfizer, Merck, Cadila Pharmaceuticals and Sabinsa Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cox-2 Inhibitors market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Selective Cox-2 Inhibitors
Non Selective Cox-2 Inhibitors

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Novartis
Pfizer
Merck
Cadila Pharmaceuticals
Sabinsa Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.